FDA calls for black box on antidepressants

Share this article:
The FDA will require that all antidepressants carry a "black box" warning highlighting the increased risk of suicidal thoughts and behavior in children and adolescents.
The "black box" warning is the most serious warning that can be placed in the labeling of prescription medication and calls for limits to be placed on advertising of the labeled products. Advertisements for drugs with the label designation, known throughout the industry as reminder ads, are forbidden. Also, the information within the boxed warning must appear in any printed ad material and must be stated exactly within any non-printed material.
In 2003, the SSRI/SNRI antidepressants category ranked third among therapeutic classes with sales of $10.9 billion in the United States, according to IMS Health. Pfizer's Zoloft, was the top-seller at roughly $2.6 billion.
Eli Lilly's Prozac is the only medication approved to treat depression in children and adults.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...